Ecraid
@ecraid.bsky.social
The European Clinical Research Alliance for Infectious Diseases is a not-for profit foundation that advances clinical research in infectious diseases.
💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier.
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
November 7, 2025 at 8:57 AM
💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier.
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease.
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
November 6, 2025 at 10:48 AM
💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease.
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
November 3, 2025 at 1:32 PM
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
October 20, 2025 at 7:24 AM
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
October 17, 2025 at 12:14 PM
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
💡 The Penta Brighter Future Award provides essential recognition and funding to individuals driving change in maternal and child health.
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
October 16, 2025 at 9:02 AM
💡 The Penta Brighter Future Award provides essential recognition and funding to individuals driving change in maternal and child health.
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
October 14, 2025 at 10:54 AM
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
October 13, 2025 at 12:08 PM
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them:
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
Accelerate Infectious Disease Trials | Ecraid
Accelerate infectious disease research with Ecraid's innovative trial designs and extensive European network for efficient, high-quality clinical trials.
bit.ly
October 7, 2025 at 11:56 AM
The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them:
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼
@escmid.bsky.social @cmicomms.bsky.social
@escmid.bsky.social @cmicomms.bsky.social
Now online: our commentary on the topic of initial antibiotic therapy in patients hospitalized with pneumonia. 👇
💣 Spoiler alert: we need to change rules if we want the best therapy for our patients.
www.clinicalmicrobiologyandinfection.org/action/showP...
💣 Spoiler alert: we need to change rules if we want the best therapy for our patients.
www.clinicalmicrobiologyandinfection.org/action/showP...
Empiric antibiotics for moderate-severe community-Acquired Pneumonia: We ought to serve patients better!
Each day thousands of patients are hospitalized worldwide with Community-Acquired
Pneumonia (CAP), either radiologically confirmed or presumed based on clinical symptoms
only, and each day physicians ...
www.clinicalmicrobiologyandinfection.org
September 30, 2025 at 1:15 PM
Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼
@escmid.bsky.social @cmicomms.bsky.social
@escmid.bsky.social @cmicomms.bsky.social
On 15-SEP, the annual #PNEUMO EU F2F meeting with Ecraid’s operational team and funder MSD took place.
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
September 24, 2025 at 7:43 AM
📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones!
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: info@ecraid.eu
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: info@ecraid.eu
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
September 15, 2025 at 9:40 AM
📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones!
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: info@ecraid.eu
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: info@ecraid.eu
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
🦠 Can respiratory viruses like SARS-CoV-2 and influenza reactivate dormant cancer cells? Although widely regarded as a scientific breakthrough and despite firm conclusions, some emphasised that cancer survivors should not be alarmed yet. Read the latest blog post by @marcbonten.bsky.social
Can acute COVID-19 awaken dormant cancer cells?
An important study, recently published.
My blog on the translation of experimental findings in mice to observational population-based data in men. 👇
letstalkscience.eu/2025/08/18/c...
An important study, recently published.
My blog on the translation of experimental findings in mice to observational population-based data in men. 👇
letstalkscience.eu/2025/08/18/c...
Can acute COVID-19 awaken dormant cancer cells? - Let's Talk Science with Marc Bonten
Yes, according to this study, which was the talk of the summer. In short: In mice experimental lung infection with SARS-CoV-2 and influenza reactivated dormant breast cancer cells, rapidly leading to ...
letstalkscience.eu
August 19, 2025 at 8:47 AM
🦠 Can respiratory viruses like SARS-CoV-2 and influenza reactivate dormant cancer cells? Although widely regarded as a scientific breakthrough and despite firm conclusions, some emphasised that cancer survivors should not be alarmed yet. Read the latest blog post by @marcbonten.bsky.social
Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...
July 23, 2025 at 12:23 PM
Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...
Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
July 14, 2025 at 9:55 AM
Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you!
More info 👉 www.ecraid.eu/careers
More info 👉 www.ecraid.eu/careers
July 9, 2025 at 9:27 AM
We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you!
More info 👉 www.ecraid.eu/careers
More info 👉 www.ecraid.eu/careers
📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones.
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
July 8, 2025 at 12:53 PM
📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones.
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by Dr.@denisevanhout.bsky.social, the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...
July 7, 2025 at 9:33 AM
What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by Dr.@denisevanhout.bsky.social, the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...
Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic.
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
July 3, 2025 at 1:16 PM
Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic.
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
💡New publication!
Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design.
📖 bit.ly/45GgWUT
#ResearchCollaboration #HORIZON2020
@advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social
Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design.
📖 bit.ly/45GgWUT
#ResearchCollaboration #HORIZON2020
@advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social
June 26, 2025 at 9:05 AM
💡New publication!
Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design.
📖 bit.ly/45GgWUT
#ResearchCollaboration #HORIZON2020
@advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social
Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design.
📖 bit.ly/45GgWUT
#ResearchCollaboration #HORIZON2020
@advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social
#DKY that in our post-grad course you can choose between two tracks, join parallel workshops, discuss real-world cases, & network with your peers? 💡
👀Check out the programme, apply for an attendance grant, or register directly to secure your place!
➡️ bit.ly/44a1tdn
#IDSky #ResearchSky #Education
👀Check out the programme, apply for an attendance grant, or register directly to secure your place!
➡️ bit.ly/44a1tdn
#IDSky #ResearchSky #Education
June 18, 2025 at 7:42 AM
#DKY that in our post-grad course you can choose between two tracks, join parallel workshops, discuss real-world cases, & network with your peers? 💡
👀Check out the programme, apply for an attendance grant, or register directly to secure your place!
➡️ bit.ly/44a1tdn
#IDSky #ResearchSky #Education
👀Check out the programme, apply for an attendance grant, or register directly to secure your place!
➡️ bit.ly/44a1tdn
#IDSky #ResearchSky #Education
Proud of our partners at University of Geneva for having published an ECRAID-Base article investigating additional analysis methods for the novel Personalised Randomised Controlled Trial (PRACTical) design in @springernature.com:
👉 www.ecraid.eu/projects/ecr...
👉 www.ecraid.eu/projects/ecr...
June 13, 2025 at 11:06 AM
Proud of our partners at University of Geneva for having published an ECRAID-Base article investigating additional analysis methods for the novel Personalised Randomised Controlled Trial (PRACTical) design in @springernature.com:
👉 www.ecraid.eu/projects/ecr...
👉 www.ecraid.eu/projects/ecr...
REMAP-CAP has published a paper in @springernature.com's Intensive Care Medicine Journal investigating whether hydrocortisone improves mortality in severe community-acquired pneumonia 👉 link.springer.com/article/10.1...
#Pneumonia #ClinicalTrials #REMAPCAP
#Pneumonia #ClinicalTrials #REMAPCAP
June 11, 2025 at 3:17 PM
REMAP-CAP has published a paper in @springernature.com's Intensive Care Medicine Journal investigating whether hydrocortisone improves mortality in severe community-acquired pneumonia 👉 link.springer.com/article/10.1...
#Pneumonia #ClinicalTrials #REMAPCAP
#Pneumonia #ClinicalTrials #REMAPCAP
📩Check our latest newsletter for: highlights from our recent meeting with key primary care representatives, new collaborations (VAC4EU) and upcoming educational opportunities.
👉🏽Registration is open for the Postgraduate course in Athens!
📫Stay informed, subscribe now: bit.ly/EcraidJune25
👉🏽Registration is open for the Postgraduate course in Athens!
📫Stay informed, subscribe now: bit.ly/EcraidJune25
June 10, 2025 at 1:49 PM
📩Check our latest newsletter for: highlights from our recent meeting with key primary care representatives, new collaborations (VAC4EU) and upcoming educational opportunities.
👉🏽Registration is open for the Postgraduate course in Athens!
📫Stay informed, subscribe now: bit.ly/EcraidJune25
👉🏽Registration is open for the Postgraduate course in Athens!
📫Stay informed, subscribe now: bit.ly/EcraidJune25
Diagnosing & treating infections in #ICUs is complex due to the need for rapid intervention and growing antibiotic resistance. Our head of CLIN-Net Miranda Hopman is at the Intensive Medicine Congress in Lisbon to discuss future collabos & share expertise on building a 'warm-base' research network.
May 30, 2025 at 10:41 AM
Diagnosing & treating infections in #ICUs is complex due to the need for rapid intervention and growing antibiotic resistance. Our head of CLIN-Net Miranda Hopman is at the Intensive Medicine Congress in Lisbon to discuss future collabos & share expertise on building a 'warm-base' research network.